Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies

Table 3

Descriptive statistics CLL (Rai staging).

Stadium (Rai)	0	I	II	III	IV	Total
IgG (g/L)	10.14	6.80	8.22	7.94	5.80	8.26
	(8.68; 13.18)	(5.36; 8.82)	(7.08; 10.07)	(6.29; 11.15)	(4.15; 7.64)	(5.84; 10.75)
IgA(g/L)	1.75	0.43	1.21	0.73	0.45	0.82
	(1.17; 2.09)	(0.38; 0.53)	(0.76; 1.72)	(0.49; 0.91)	(0.35; 0.83)	(0.48; 1.69)
IgM(g/L)	0.79	0.29	0.43	0.30	0.24	0.46
	(0.57 ;0.83)	(0.21; 0.45)	(0.33 ;0.65)	(0.20; 0.62)	(0.12; 0.47)	(0.26; 0.81)
Anti-Gal IgG (U/L)	65.32	35.80	29.70	49.78	10.42	45.88
	(18.73; 132.10)	(2.73; 50.51)	(0.78; 57.09)	(4.38; 85.90)	(1.78; 86.15)	(13.69; 80.21)
Anti-Gal IgA (U/mL)	11.80	2.37	5.9	4.70	2.84	5.35
	(8.23; 16.39)	(1.56; 6.31)	(3.05; 8.33)	(3.38; 9.19)	(1.07; 5.19)	(2.93; 11.16)
Anti-Gal IgM (U/mL)	10.22	9.41	3.74	6.87	1.89	5.7
	(6.19; 20.05)	(2.42; 13.97)	(1.75; 7.57)	(1.59; 11.96)	(1.25; 3.35)	(1.97; 11.31)
Anti-PCP IgG (mg/L)	62.66	45.72	30.4	42.58	20.86	41.10
	(38.18; 89.64)	(36.57; 57.67)	(15.69; 56.06)	(15.42; 73.97)	(17.32; 37.50)	(19.09; 68.17)
Anti-PCP IgG2 (mg/L)	24.28	19.10	10.86	10.19	7.14	13.73
	(13.96; 29.86)	(14.80; 23.43)	(5.32; 18.38)	(4.48; 21.35)	(6.60; 11.43)	(7.05; 24.49)
Anti-PCP IgA (mg/L)	15.64	6.41	10.57	6.97	3.74	7.58
	(9.62; 22.58)	(4.20; 10.30)	(5.65; 24.78)	(3.79; 9.37)	(3.23; 4.67)	(4.16; 17.52)

Because the data were not normally distributed, they are shown as the median, Q1 (first quartile), and Q3 (third quartile).